Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

ASCO17: Days 4 and 5 Immunotherapy Highlights

June 06, 2017

Days 4 and 5 at ASCO17 showed off the overall scope of immunotherapy’s efforts to provide clinical benefits to patients. Many next-generation immune-based treatments were discussed, including some of which may represent the future standard of care for some cancers. Below are some of the most important findings revealed during the final two days of the conference:

Multiple Tumor Types:

Bladder Cancer:

Brain Cancer:

Watch our story about Carol, one of the patients treated on this trial.

  • In a phase I/II clinical trial, the immunotherapy combination of VB-111 (blood vessel-targeting adenovirus) plus bevaicuzmab (anti-VEGF antibody) provided long-term activity and was associated with increased overall in patients with glioblastoma. http://abstracts.asco.org/199/AbstView_199_188168.html

Breast Cancer:

  • In a phase II clinical trial, pre-surgical treatment with pembrolizumab (anti-PD-1 checkpoint immunotherapy) plus a standard chemotherapy regimen led to significantly increased pathological complete response rates in patients with advanced breast cancer, especially those with triple-negative breast cancer (TNBC), compared to the chemotherapy regimen alone. http://abstracts.asco.org/199/AbstView_199_194235.html
  • In a phase III clinical trial, adding pertuzumab (anti-HER2 antibody immunotherapy) to the combination of trastuzumab (anti-HER2 antibody immunotherapy) and chemotherapy increase the rate of invasive disease-free survival in patients with early stage HER2+ breast cancer.  http://abstracts.asco.org/199/AbstView_199_189357.html
  • In a phase I/II clinical trial, MCLA-128 (bi-specific antibody immunotherapy targeting both HER2 and HER3) appeared to be effective in patients with heavily pre-treated, HER2+ metastatic breast cancer. http://abstracts.asco.org/199/AbstView_199_187396.html

Childhood Cancer:

  • Treatment with inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate immunotherapy) was associated with a high complete response rate (62%) in patients with heavily pre-treated acute lymphoblastic leukemia (ALL). http://abstracts.asco.org/199/AbstView_199_191282.html

Colorectal Cancer:

Head and Neck Cancer:

Kidney Cancer:

  • In a phase I clinical trial, CPI-444 (anti-A2AR checkpoint immunomodulator) appeared to be effective both alone and in combination with atezolizumab (anti-PD-L1 checkpoint immunotherapy) in kidney and lung cancer patients for whom prior anti-PD-1/PD-L1 checkpoint immunotherapy was ineffective, as well as those whose tumors didn’t express PD-L1. (Lawrence Fong, M.D., gave the oral presentation of this work, in which Joshua Brody, M.D., was also involved.) http://abstracts.asco.org/199/AbstView_199_186068.html
  • In a phase I clinical trial, first-line treatment with the combination of avelumab (anti-PD-L1 checkpoint immunotherapy) plus chemotherapy demonstrated promise in patients with advanced kidney cancer. http://abstracts.asco.org/199/AbstView_199_183536.html
  • In a phase II clinical trial, the combination of atezolizumab (anti-PD-L1 checkpoint immunotherapy) and bevacizumb (anti-VEGF antibody immunotherapy) showed effectiveness as a first-line treatment in patients with PD-L1+ metastatic kidney cancer, as well as those who received the combination after prior therapy. http://abstracts.asco.org/199/AbstView_199_190962.html
  • In a phase I clinical trial, PF-8600 (OX40 agonist antibody immunotherapy) appeared to be effective in patients with advanced head and neck cancer, kidney cancer, liver cancer, and melanoma. http://abstracts.asco.org/199/AbstView_199_184208.html


Liver Cancer:

Lung Cancer:



Multiple Myeloma:

Ovarian Cancer:

Pancreatic Cancer:

Prostate Cancer:


  • In a pilot clinical trial, treatment with T cells that were genetically engineered to target the NY-ESO-1 protein, in combination with chemotherapy, demonstrated clinical benefits in patients with NY-ESO-1+ synovial sarcoma. http://abstracts.asco.org/199/AbstView_199_193450.html